Allworth Financial LP Takes Position in Edwards Lifesciences Corporation $EW

Allworth Financial LP bought a new position in Edwards Lifesciences Corporation (NYSE:EW - Free Report) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 16,600 shares of the medical research company's stock, valued at approximately $1,502,000.

A number of other hedge funds have also modified their holdings of EW. Hanson & Doremus Investment Management purchased a new position in shares of Edwards Lifesciences in the first quarter worth approximately $25,000. JPL Wealth Management LLC acquired a new position in Edwards Lifesciences in the 3rd quarter worth about $25,000. MV Capital Management Inc. bought a new stake in shares of Edwards Lifesciences during the 4th quarter worth about $26,000. RMG Wealth Management LLC acquired a new stake in shares of Edwards Lifesciences in the first quarter worth $26,000. Finally, TrinityBridge Ltd bought a new position in Edwards Lifesciences in the 2nd quarter worth approximately $27,000. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, VP Donald E. Bobo, Jr. sold 23,145 shares of Edwards Lifesciences stock in a transaction on Wednesday, May 27th. The shares were sold at an average price of $86.42, for a total value of $2,000,190.90. Following the completion of the sale, the vice president owned 98,611 shares in the company, valued at $8,521,962.62. The trade was a 19.01% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Daniel J. Lippis sold 619 shares of the stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $92.03, for a total transaction of $56,966.57. Following the transaction, the vice president directly owned 40,034 shares in the company, valued at $3,684,329.02. This trade represents a 1.52% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 25,570 shares of company stock valued at $2,219,390 in the last three months. Insiders own 0.31% of the company's stock.

Edwards Lifesciences Price Performance

Shares of Edwards Lifesciences stock opened at $89.89 on Friday. The company has a quick ratio of 3.77, a current ratio of 4.52 and a debt-to-equity ratio of 0.06. The stock has a market capitalization of $51.76 billion, a price-to-earnings ratio of 51.66, a price-to-earnings-growth ratio of 2.26 and a beta of 0.85. Edwards Lifesciences Corporation has a twelve month low of $72.30 and a twelve month high of $96.29. The company has a 50-day simple moving average of $89.21 and a two-hundred day simple moving average of $84.67.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 EPS for the quarter, topping analysts' consensus estimates of $0.74 by $0.04. The firm had revenue of $1.74 billion for the quarter, compared to analyst estimates of $1.70 billion. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The company's revenue was up 13.6% on a year-over-year basis. During the same quarter last year, the company earned $0.67 EPS. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Analysts forecast that Edwards Lifesciences Corporation will post 3 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have commented on EW shares. Piper Sandler restated an "overweight" rating and set a $101.00 price target (up from $100.00) on shares of Edwards Lifesciences in a research note on Friday, July 24th. Leerink Partners raised shares of Edwards Lifesciences from a "market perform" rating to an "outperform" rating and boosted their target price for the stock from $87.00 to $101.00 in a research note on Friday, July 24th. Mizuho lifted their price objective on Edwards Lifesciences from $100.00 to $105.00 and gave the stock an "outperform" rating in a research note on Wednesday, July 15th. TD Cowen reiterated a "buy" rating on shares of Edwards Lifesciences in a report on Tuesday, July 21st. Finally, Royal Bank Of Canada upped their target price on Edwards Lifesciences from $100.00 to $110.00 and gave the stock an "outperform" rating in a report on Monday, July 13th. Seventeen investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $100.27.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source